-
The Isolation of Intact Chloroplasts
Time of Update: 2021-01-19
The latter is important in the case of the plant molecular biologist wishing to study the subcellular localization of a given protein.
-
Rio Tinto's iron ore shipments rose 1.5 per cent in the second quarter due to strong Chinese demand
Time of Update: 2020-07-27
shipments of 86.7m tonnes of iron ore from the quarter ended June 30, compared with 85.4m tonnes a year earlier.
-
Ivertinib, the original drug of Essen medicine, has initial clinical effect and breaks through the difficult problem of targeted treatment of lung cancer
Time of Update: 2020-04-03
In the next key clinical study of ivetinib, Wu Yilong said that the clinical study will verify the results achieved in phase I, shorten the market time of the drug, and benefit more lung cancer patients with greater welfare.
-
Marketing: advertising strategy for key target market of coating enterprises
Time of Update: 2020-04-03
Core tip: every developing coating enterprise wants to show its head in the process of participating in the market competition
However, the large-scale behavior of fully
-
Mb07133, a new targeted drug of Xi'an Xintong drug, class 1.1 liver cancer, obtained clinical approval
Time of Update: 2020-04-03
Based on the liver targeting technology, mb07133 can concentrate the drug concentration in the liver, improve the curative effect, significantly reduce the systemic exposure of the drug, and reduce the toxicity of plasma, bone marrow and extrahepatic tissues.
-
Xi'an Xintong 1.1 liver cancer targeting new drug "mb07133 for injection" obtained clinical approval
Time of Update: 2020-04-03
It is estimated that after mb07133 goes on the market, the daily cost of medicine will be 500 yuan, which will greatly reduce the burden of patients while satisfying the clinical medication.
-
Roche's Chugai non-small cell lung cancer targeting drug alectinib approved by Japan
Time of Update: 2020-04-03
Alectinib, the latest targeted drug for anaplastic lymphoma kinase (ALK) - positive non-small cell lung cancer, has been approved for the first time in Japan
The anti
-
Marketing: how to transform target customers into ultimate customers
Time of Update: 2020-04-03
It is suitable for leather Coating home news: in the process of coating sales, it is necessary to transform ordinary target customers into brand loyal customers through at least the following five stages.
-
Nanfang pharmaceutical a new type of new targeted nano Paclitaxel injection (Xinsu) is expected to complete preclinical research in 2017
Time of Update: 2020-04-03
It is a new injection developed independently by Nanfang pharmaceutical company, which combines modern polymer micelle technology with paclitaxel, an anti-tumor drug.
-
Marketing: three step negotiation of developing target customers for coating enterprises
Time of Update: 2020-04-03
Core tip: the so-called negotiation means that after the first round of visit and negotiation, i.e
after market sweeping, target customers meeting our investment
-
Apg-115, an original and new target precise antitumor drug of AXA pharmaceutical, was approved to enter the US clinical practice
Time of Update: 2020-04-03
June 2, 2016 - on June 1, according to the information from FDA, apg-115, a precision anti-tumor drug with global intellectual property rights and acting on the new target MDM2-p53
-
Marketing: problems to be paid attention to in setting the sales target of coatings
Time of Update: 2020-04-03
Core tip: the following six aspects should be paid attention to when setting the sales target of coatings: (1) the specificity of coatings sales
The objectives should
-
Promotion of new clinical dosage forms of five new tumor targeting drugs approved by Hengrui medicine
Time of Update: 2020-04-03
At present, including Hengrui medicine, there are three domestic manufacturers of irinotecan common preparations.
-
Zaiding Pharmaceutical Co., Ltd. and South Korea and the United States jointly develop EGFR targeted lung cancer drug hm61713
Time of Update: 2020-04-03
South Korea and the United States are eager to bring new treatment options for lung cancer patients in China as soon as possible.
-
Migraine competition intensified! The fourth CGRP targeted antibody, Lingbei vyepti, was approved by the FDA of the United States. It was infused once every 3 months
Time of Update: 2020-02-23
Lundbeck recently announced that the U.S
Food and Drug Administration (FDA) has approved vyepti (eptinezumab jjmr) for preventive treatment of adult migraine
-
Migraine competition intensified! The fourth CGRP targeted antibody, Lingbei vyepti, was approved by the FDA of the United States. It was infused once every 3 months
Time of Update: 2020-02-23
February 23, 2020 / BIOON / -- lundbeck recently announced that the U.S. Food and Drug Administration (FDA) has approved vyepti (eptinezumab jjmr) for the preventive treatment of adult migraine.
-
Targeting the surrounding tissue of cancer cells or inhibiting cancer metastasis
Time of Update: 2020-02-21
Researchers want to target these cells, but first they need to know more about this supportive system and how it promotes tumor growth and metastasis.
-
Science subjournal: tumor specific antibody targeted inhibition of Ras mutant tumors
Time of Update: 2020-02-20
Injecting inras37 into mice with small rasmut xenograft tumor by systemic administration can produce strong antitumor activity, but this antibody has little effect on the downstream rasmut tumor with simultaneous PI3K mutation, which can be overcome by combining PI3K inhibitor.
-
Targeting around cancer tissue may inhibit or limit cancer metastasis
Time of Update: 2020-02-20
Understanding the mechanism of communication between CAFs and blood vessels may reveal a new way to block the spread of cancer.
-
Tumor specific cytoplasmic targeting of Ras mutants can inhibit tumor growth
Time of Update: 2020-02-20
Injecting inras37 into mice with small rasmut xenograft tumor by systemic administration can produce strong antitumor activity, but this antibody has little effect on the downstream rasmut tumor with simultaneous PI3K mutation, which can be overcome by combining PI3K inhibitor.
